Cervical Granulocytic Sarcoma
Zhang Guo-nan,Song Shui-qin,Zhu Yi,Shi Yu,Li Ji-man
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130941
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:To the editor: a 34 year-old (gravida one, para one) female with a 1-year history of menorrhagia diagnosed 5 days earlier with cervical cancer was admitted to our hospital on April 16th, 2009. Previous medical history and family history were not remarkable, and physical examination was normal. Gynecologic examination showed normal vagina with an 8 cm diameter hard cervical mass that bled easily. The uterus was normal and movable. No mass was found in the adnexal area. Lateral ligaments were not thickened. Ultrasound indicated cervical diameter was 5.9 cm with 5.7 cm × 5.8 cm low echo mass be identified. A cervical biopsy done after admission, the pathologic finding showed diffuse, medium-sized oval or round cells with high nuclear/cytoplasm ratio. Nuclei had an oval shape with weak basophilic staining and reticular-like chromatin with scantly distributed eosinophils. Nucleoli was small and immature. No cervical epithelial or glandular cells can be seen (Figure 1A). Immunohistochemical analyses showed myeloperoxidase (MPO) (+), synapsin (Syn) (-), chromogranin (CgA) (-), and T-cell surface markers CD3(-), CD20(-) (Figure 1B). A diagnosis of granulocytic sarcoma of cervix stage Ib2, immature type was made based on the pathologic findings. However, bone marrow biopsy and routine blood test were normal. Neoadjuvant chemotherapy was administered prior to surgery due to the large size of the tumor. Beginning on April 27, the patient was administered one course of neoadjuvant chemotherapy (Paclitaxel 180 mg plus Epirubicin 70 mg given intravenously). No obvious effect was observed after the first course of chemotherapy, so the chemotherapy regimen was changed. Next the patient received 3 courses of Cytarabine (Ara-C) 100 mg day 1–7, and Daunorubicin 60 mg day 1–3 on May 20, June 14, and July 10, respectively. After a total of 4 courses of chemotherapy, the tumor size was reduced dramatically. Gynecologic examination showed the cervix had a normal appearance with diameter of 3cm. Then radical hysterectomy with bilateral salpingectomy, right adnexal cyst removal and ovarian transposition was performed. During the operation, no abnormal tissue was observed in the muscularis layer and endometrium of uterus. The 3-cm cervix was rigid. No tumor cells were found in multiple postoperative cervix biopsies. No lymph node metastatses were found. A right ovarian vesicular cyst was diagnosed. Another 3 courses of chemotherapy with Ara-C and Daunorubicin were administered after surgery. The patient is currently in remission, with no evidence of relapse at the most recent follow-up examination.Figure 1. A:: H&E stain of Cervical Granulocytic Carcoma (Haematoxylin and eosin staining, original magnification × 400). B: Immunostaining for MPO in Cervical Granulocytic Carcoma (original magnification ×400).Granulocytic sarcoma is a rare malignant myelogenous tumor, consisting of myeloblastoma or poorly differentiated myelogenous cells.1 It often presents as a solid tumor in bone or other extramedullary sites, accompanied by AML, chronic myelogenous leukemia, chronic idiopathic myelofibrosis, eosinophilia, or polycythemia vera. It is called isolated granulocytic sarcoma when there is no leukemia in the peripheral blood and bone marrow. This case is an example. Granulocytic sarcoma is rarely seen as an isolated mass in the cervix. Granulocytic sarcoma of the cervix appears smooth, with solid texture, evenly distributed on the section. Because a green tint appears on the outside due to the presence of MPO, it is also called a chloroma. Microscopically immature cells are present. Examination for cells with granulocytic character, and myeloblasts and promyelocytes is essential. Immunohistochemistry and cytology can be of great help in diagnosis. MPO is a commonly used test, with positive rate 77% to 97% and high sensitivity and specificity, expressed in every stage of granulocytic differentiation. The prognosis is affected mainly by treatment strategy. Timely diagnosis and treatment can prevent leukemia in 25% to 66% of patients versus 3% to 13% without treatment. The treatment includes systemic chemotherapy and radiation. Systemic chemotherapy against AML is the first-line treatment for granulocytic sarcoma, even without leukemia. For the larger occupied mass, systemic chemotherapy is necessary following surgery plus local radiotherapy. An antileukemic chemotherapeutic regimen is suggested. In this case, neoadjuvant chemotherapy plus surgery plus adjuvant chemotherapy consisting of Ara-C and Daunorubicin was used, and effective. The prognosis in cervical granulocytic sarcoma is poor; the mean survival time in the cases reported to date was 7.6 months (range: 9–36 months).2 Some patients obtained complete remission after chemotherapy and had longer survival. Follow-up in our case is now 42 months and has no relapse. Neoadjuvant chemotherapy and surgery followed postoperatively by systemic chemotherapy proved to be feasible with acceptable toxicity and good outcome in a patient considered at cervical granulocytic sarcoma. Although observations are restricted to one single patient and long-term follow-up is required, the described regimen may open a potentially curative perpective and warrants further investigation.